Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant

Sayami Ito1, Sachiko Hirobe2,3,4, Takuto Kawakita1

  • 1Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.

Pharmaceutics
|March 19, 2020
PubMed